• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 01 2021

QTE Development

-

February 8, 2021

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:22 am

Published: February 8, 2021

Top stories

Collaboration – September 8, 2026

HeartBeat.bio and Cubase Bio partner to advance 3D spatial transcriptomics

Vienna-based HeartBeat.bio and Stockholm-based Cubase Bio have been awarded roughly EUR 1 million in Eurostars funding to develop a 3D spatial profiling method for studying myocardial fibrosis and heart failure, combining human cardiac organoids with true 3D spatial transcriptomics technology.

Science News – September 8, 2026

“Our study is an example of the shift toward targeting cancer metabolism inside the cell”

Researchers at the University of Gothenburg have developed a treatment for acute myeloid leukemia that forces cancer cells to run at full throttle while cutting off their energy supply, driving them to burn out and die from the stress. The first study in mice shows highly promising results.

Collaboration – September 8, 2026

Klaria and RTHS partner to enable earlier detection and treatment of migraine

Klaria has entered a collaboration agreement with RTHS to combine RTHS’s sensor-based measurements of blood flow dynamics with Klaria’s approved migraine treatment, aiming to detect migraine attacks before symptoms set in.

SwedenBIO – September 8, 2026

Why we are mapping Swedish medtech innovation

When people think of life science innovation, they often think of new medicines. Yet many of the innovations transforming healthcare today – from AI-powered diagnostics to robotic surgery and remote patient monitoring – are driven by medtech companies. With my own multiyear background in the medtech industry, this section of life science has a special place in my heart.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Collaboration - September 8, 2026

HeartBeat.bio and Cubase Bio partner to advance 3D spatial transcriptomics

Vienna-based HeartBeat.bio and Stockholm-based Cubase Bio have been awarded roughly EUR 1 million in Eurostars funding to develop a 3D spatial profiling method for studying myocardial fibrosis and heart failure, combining human cardiac organoids with true 3D spatial transcriptomics technology.

Science News - September 8, 2026

“Our study is an example of the shift toward targeting cancer metabolism inside the cell”

Researchers at the University of Gothenburg have developed a treatment for acute myeloid leukemia that forces cancer cells to run at full throttle while cutting off their energy supply, driving them to burn out and die from the stress. The first study in mice shows highly promising results.

Collaboration - September 8, 2026

Klaria and RTHS partner to enable earlier detection and treatment of migraine

Klaria has entered a collaboration agreement with RTHS to combine RTHS's sensor-based measurements of blood flow dynamics with Klaria's approved migraine treatment, aiming to detect migraine attacks before symptoms set in.

SwedenBIO - September 8, 2026

Why we are mapping Swedish medtech innovation

When people think of life science innovation, they often think of new medicines. Yet many of the innovations transforming healthcare today – from AI-powered diagnostics to robotic surgery and remote patient monitoring – are driven by medtech companies. With my own multiyear background in the medtech industry, this section of life science has a special place in my heart.

Clinical Trials - September 8, 2026

SynAct’s new data analysis bolsters case for Phase 3 RA trial

A post-hoc analysis of SynAct Pharma's Phase 2b ADVANCE study confirms earlier positive results for resomelagon in rheumatoid arthritis (RA), and the company now plans to discuss Phase 3 trial design with the FDA in Q4 2026.

Science News - September 7, 2026

Remembering Nobel laureate Ada Yonath

Ada Yonath, the 2009 Nobel laureate in Chemistry, died on August 31, 2026, at the age of 87. She was one of the first Nobel Prize laureates I interviewed as a new editor at Nordic Life Science – and the first I met in person, over an interview at the Grand Hotel in Stockholm. Yonath, who in 2009 became the first woman in 45 years to win the Nobel Prize in Chemistry, spoke to me about her curiosity, polar bears, extremely durable bacteria from the Black Sea, and her passion for science.

MedTech Business - September 7, 2026

Neola Medical wins FDA Breakthrough Device Designation

Neola Medical has been granted Breakthrough Device Designation by the US FDA for Neola, its non-invasive lung monitor for preterm babies, designed to give early warning of life-threatening lung collapse.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.